Introduction
Efforts to define immune correlates of protection against HIV propose a key role to some major histocompatibility complex (MHC) class I alleles and to qualitative parameters of HIV-specific CD8 þ T cells [1] [2] [3] [4] [5] [6] . The human leukocyte antigen (HLA)-B27, B57, or the closely related B5801 (HLA-B57/5801), alleles dictate robust HIV-specific CD8 þ T cells that are associated with HIV control [7] [8] [9] [10] [11] [12] . Antigen specificity of CD8 þ T cells also appears to be critical with a stronger protection conferred by Gag-specific T cells [13] [14] [15] [16] [17] [18] , but mechanisms involved appear to differ and are not yet fully elucidated. HLA-B27 drives the superior antiviral efficacy of Gagspecific CD8 þ T cells in long-term nonprogressors by allowing higher cell avidity, polyfunctionality and clonal turnover [19] . In contrast to HLA-B27, which presents to CD8 þ T cells an immunodominant epitope in Gag but not in Nef, HLA-B57/5801 present several Gag and Nef epitopes [20, 21] . In HLA-B57/5801 þ individuals Gag-specific T cells appear to mediate a superior antiviral control than Nef ones [13] , although the latter was shown to be preserved in HLA-B57/5801 þ nonprogressors [22] . However, little attention has been paid thus far to the differentiation triggered by specific HIV antigens in HLA-B57/5801 þ nonprogressors and their association with disease protection. Therefore deciphering the relative properties of HIV-specific CD8 þ T cells against the Gag and Nef epitopes in HLA-B57/5801 þ nonprogressors should help further understand the protective effect of HIV-specific CD8 þ T cells.
In order to identify attributes of the CD8 þ T-cellmediated protection against HIV in HLA-B57/5801 þ nonprogressors, we investigated in HLA-B57/5801positive and negative individuals, whether antigen specificity and HLA restriction trigger distinct patterns of cell differentiation that could explain the association between HLA-B57/5801 and virus control.
Materials and methods
Patients Samples were obtained from 53 French ALT-ANRS-CO15 cohort patients (Supplemental Table 1 , http:// links.lww.com/QAD/A70). As described [23, 24] , inclusion criteria in the cohort were: HIV seropositivity for at least 8 years, CD4 cell counts above 600/ml for the last 5 years without symptoms or antiretroviral therapy. The median length of HIV seropositivity was 9 years at entry into the cohort [23] . The study was approved by the institutional review board at the Pitié-Salpêtrière Hospital, and all patients provided written informed consent.
HLA genotyping HLA genotyping was performed by amplification refractory mutation system PCR, with sequence-specific primers [25] .
Parameters of HIV production
Plasma HIV-RNA were quantified as described [23, 24] . The HIV-DNA in PBMCs was quantified with a modified Amplicor Monitor assay (Roche Laboratories) with a cutoff value of 5 copies of HIV-DNA/10 6 PBMC [24] .
Synthetic peptides
Synthetic 15-mer peptides overlapping by 11 amino acids (Neosystem, France) and spanning the HIV-HxB2 Gag and Nef sequences were combined into 11 and 3 pools, respectively. Eight CD8 þ T-cell epitopes derived from HIV-HxB2 Gag or Nef were synthesized according to the Los Alamos HIV database. The B57-restricted peptides were: ISPRTLNAW (Gag147-155, IW9), KAFSPEVIPMF (Gag162-172, KF11), TSTLQEQIGW (Gag240-249, TW10), and HTQGYFPDW (Nef116-124, HW9). The A3-restricted peptides were: KIRLRPGGK (Gag18-26, KK9), and QVPLRPMTYK (Nef73-82, QK10). The A26-restricted peptide was EVIPMFSAL (Gag167-175, EL9). Lastly, the B35restricted peptide was TPGPGVRYPL (Nef128-137, TL10).
IFN-g enzyme-linked immunospot assay
PBMCs were incubated with phytohaemagglutinin (positive control), medium alone (negative control), Gag and Nef peptide pools as described [24] . Spots were considered positive if above 50 SFC/10 6 PBMCs after subtracting background. Functional avidity was assessed by testing serial 10-fold dilutions ranging from 100 to 0.0001 mg/ml of optimal peptides and determining the peptide concentration inducing half-maximal responses in enzyme-linked immunospot (ELISpot) assays [19] .
Intracellular cytokine staining, phenotyping and tetramer staining
PBMCs were incubated overnight with staphylococcal enterotoxin b (positive control), medium (negative control), Gag and Nef pools found to be positive in the ELISpot assay. Brefeldin-A was added as described [26] . Cells were stained with anti-CD8-PE-Cy7, anti-CD45RA-ECD (Beckman-Coulter), anti-CCR7-PE (R&D System), anti-CD27-FITC and anti-IFN-g-APC and/or anti-IL-2-PE (Becton Dickinson). Cells were analyzed on a Beckman Coulter FC500 flow cytometer using the CXP Analysis (Beckman Coulter) software. The CD3 þ CD8 þ CD45RA -CD27 þ/-CCR7 þ/-IFN-g þ cells accounted for up to 99% of the CD8 þ CD45RA -CD27 þ/-CCR7 þ/-IFN-g þ cells as analyzed in parallel on a FACSCanto-I flow cytometer (Becton Dickinson), thus assessing the T-cell nature of the IFNg-producing CD8 þ cells. CD27 expression on CD8 þ T cells binding the B57/KF11 tetramer (Beckman-Coulter) was also analyzed in combination with anti-CCR7-PE-Cy7, anti-CD27-APC, anti-CD8-APC-Cy7 (Becton Dickinson), and anti-CD45RA-FITC (Beckman-Coulter) by a FACSCanto-I flow cytometer and the FlowJo (version 8.0, TreeStar) software on three HLA-B57/ 5801 þ individuals.
Statistical analysis
Statistics were conducted with SPSS 13.0 software (SSPS Inc., Chicago, Illinois, USA). The Wilcoxon rank sum test, Mann-Whitney U test and Spearman's rank correlation were used. The Benjamini-Holberg procedure was used to correct for the multiplicity of tests [27] and mentioned as 'corrected P' value.
Results
Frequencies of Gag-specific CD8 R T cells but not Nef-specific ones correlates negatively with cell-associated HIV-DNA In this group of 53 nonprogressors, the five-fold higher numbers of IFN-g-producing Gag-specific T cells than their Nef-specific counterparts (median: 2527 vs. 480 SFC/10 6 PBMC, corrected P < 0.0001; Supplemental Table 1 , http://links.lww.com/QAD/A70 and Fig. 1a ), negatively correlated with cell-associated HIV-DNA loads (r ¼ À0.395, corrected P ¼ 0.004; Fig. 1b ), whereas the Nef-specific ones did not (r ¼ À0.151, P ¼ 0.294; Fig. 1c ). Despite HIV-DNA loads highly correlated with plasma HIV-RNA loads (r ¼ 0.801, corrected P < 0.0001; Fig. 1f ), HIV-specific cell frequencies did not correlate with plasma HIV-RNA levels ( Fig. 1d and e ).
HLA-B57/5801 molecules are frequent in nonprogressors and associated with virus control. They restrict CD8 þ T-cell recognition of epitopes in both Gag and Nef. We further investigated whether such differences could be triggered by HLA-B57/5801. We therefore performed a head-to-head comparison of Gag and Nef-specific CD8 þ T cells in samples from 11 HLA-B57/5801 þ individuals and 11 HLA-B57/5801 À individuals with simultaneous responses to Gag and Nef peptide pools containing the HLA-B57/5801-restricted epitopes (Supplemental Table 1 , http://links.lww.com/ QAD/A70 and Supplemental Fig. 1 , http://links.lww. com/QAD/A70).
Recognition of the corresponding Gag and Nef epitopes restricted by HLA-B57/5801 and other HLA types (Supplemental Fig. 2 , http://links.lww.com/QAD/A70) confirmed differences in magnitude between these sets of cells. A multifunctional flow cytometry analysis showed few of the Gag and Nef-specific CD8 þ T cells producing IL-2 (Supplemental Fig. 3 , http://links.lww.com/QAD/ A70), regardless of HLA.
HLA-B57/5801 dictates a preferential CD27 expression of Gag-specific central memory CD8 R T cells compared to Nef ones The superior magnitude of Gag-specific IFN-g þ CD8 þ T cells compared to Nef-specific ones did not reflect a distinct repartition of the classical central and effector memory cells [central memory T cells (TCM) and effector memory T cells (TEM), respectively] in either HLA group (Supplemental Fig. 4a , http://links.lww. com/QAD/A70). However, the HLA-B57/5801 þ Gagspecific IFN-g þ IL-2 À CD8 þ T cells differed from their Nef-specific counterparts by a higher proportion of IFN-g þ CD45RA -CD8 þ cells displaying CD27 (38 vs. 26%, corrected P ¼ 0.007; Fig. 2a and Supplemental Fig. 4b , http://links.lww.com/QAD/A70). This difference was maintained in HLA-B57/5801 þ individuals between CD27 expression on 39% [interquartile range (IQR) 31-56%] of Gag-specific CD8 þ TCM cells and 33% (IQR 16-42%) of Nef-specific ones (corrected P ¼ 0.007; Fig. 2c ), but not in the HLA-B57/5801 À population ( Fig. 2b and d) . The preferential CD27 expression of HLA-B57/5801 þ TCM was observed as well on HLA-B57-tetramer binding Gag-specific CD8 þ TCM (Supplemental Fig. 5 , http://links.lww.com/QAD/ A70). A similar but not significant trend was observed on the Gag-specific TEM whatever the HLA (Fig. 2c and d) .
In contrast effector Gag and Nef-specific cells displayed similar CD27 expression (data not shown).
The preferential CD27 expression on HLA-B57/ 5801 R Gag-specific CD8 R TCM correlates with virus control The CD27 þ Gag-specific IFN-g þ CD8 þ TCM negatively correlated with both plasma HIV-RNA (r ¼ À0.502, corrected P ¼ 0.024) and HIV-DNA (r ¼ À0.567, corrected P ¼ 0.018; Fig. 2e ) in the total group. This negative correlation was maintained in the HLA-B57/5801 þ (r ¼ À0.683, corrected P ¼ 0.042; Fig. 2e ) but not in the HLA-B57/5801 À group. The Nef-specific counterpart was not correlated with either the HIV-DNA (Fig. 2f ) or the plasma HIV-RNA loads, regardless of HLA. In addition, no significant correlation was found between CD27 þ Gag or Nef-specific IFN-g þ TEM and HIV burden in either HLA group (Supplemental Table 2 , http://links.lww.com/QAD/A70).
These results show that a 37.5% Gag-specific CD27 þ TCM are required to be associated with a 1 log reduction in HIV-DNA load in the whole group. In the HLA-B57/ 5801 þ group, however, a 29% Gag-specific CD27 þ TCM is sufficient.
allowing higher numbers of Gag-specific central memory CD8 þ T cells to display CD27 compared to Nef-specific ones. These results provide new insights into the mechanisms by which protective HLA-B57/5801 alleles support superior control exerted by Gag-specific compared to Nef-specific T cells.
In addition, we provide novel evidence that the cellassociated HIV-DNA load is a better surrogate marker for cell-mediated virus control than the plasma HIV-RNA load [28] . Indeed the negative correlation observed in the whole group of nonprogressors between total Gag-specific CD8 þ T cells and cell-associated HIV-DNA is re-inforced in HLA-B57/5801 þ individuals in whom Gag-specific CD27 þ TCM correlated with cell-associated HIV-DNA load. As HIV-specific CD8 þ T cells detect infected cells producing HIV antigens but not free virus particles, and assuming the number of HIV-DNA copies per million cells roughly represents the numbers of infected cells, the cell-associated HIV-DNA more accurately reflects the infected cell targets of CD8 þ T cells than the plasma HIV load. It remains unclear yet whether the HIV-DNA load is determined by the CD8 þ T-cell phenotype or vice versa. The new characteristics we demonstrate here for HLA-B57/5801 þ Gag-specific CD8 þ T cells contrasts with previous study suggesting persistent CD27 expression explain the failure of HIV-specific CD8 þ T cells to control the virus [29] . The known property of CD27 to promote cell survival and proliferation required for the generation and long-term maintenance of antigenspecific T-cell immunity [30] fits, however, with a better control of HIV mediated by these Gag-specific CD8 þ TCM. Alternatively, stronger CD27 expression on HLA-B57/5801 þ Gag-specific CD8 þ TCM might simply reflect preferential survival in the context of a low antigen burden, although both HLA groups were comparable for CD4 cell counts and plasma viral loads.
Those distinct stages of differentiation reached by HLA-B57/5801 þ Gag and Nef-specific cells are reminiscent of a distinct differentiation pattern reported for CD8 þ T cells specific for lytic and latent Epstein-Barr virus (EBV) proteins [31] , suggesting modalities of antigen stimulation and kinetics of antigen expression may account for differences in the differentiation profiles. HIV-Nef indeed differs from Gag since expressed only in virus-producing cells, whereas the abundantly released capsid antigens can be cross-presented by professional antigen-presenting cells. Alternatively, more frequent viral escape from the Nef-specific immune response than against the Gagspecific one might account for such differences [32] [33] [34] .
More differentiated T cells, as observed for Nef-specific cells, might exert a stronger selective pressure and facilitate emergence of variants. On the contrary, structural constraints on Gag epitopes might allow specific T cells to persist in a more quiescent central-memory status.
Altogether our findings provide new insight into the immune correlates of HIV control and the mechanisms of protection conferred by HLA-B57/5801 and confirm the need for closer attention to the nature of the HIVantigens included in vaccines against HIV.
